Publication: Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors
| dc.contributor.author | Makarasen A. | |
| dc.contributor.author | Kuno M. | |
| dc.contributor.author | Patnin S. | |
| dc.contributor.author | Reukngam N. | |
| dc.contributor.author | Khlaychan P. | |
| dc.contributor.author | Deeyohe S. | |
| dc.contributor.author | Intachote P. | |
| dc.contributor.author | Saimanee B. | |
| dc.contributor.author | Sengsai S. | |
| dc.contributor.author | Boonsri P. | |
| dc.contributor.author | Chaivisuthangkura A. | |
| dc.contributor.author | Sirithana W. | |
| dc.contributor.author | Techasakul S. | |
| dc.contributor.author | Dr. | |
| dc.date.accessioned | 2021-04-05T03:04:46Z | |
| dc.date.available | 2021-04-05T03:04:46Z | |
| dc.date.issued | 2019 | |
| dc.date.issuedBE | 2562 | |
| dc.description.abstract | In this study, amino-oxy-diarylquinolines were designed using structure-guided molecular hybridization strategy and fusing of the pharmacophore templates of nevirapine (NVP), efavirenz (EFV), etravirine (ETV, TMC125) and rilpivirine (RPV, TMC278). The anti-HIV-1 reverse transcriptase (RT) activity was evaluated using standard ELISA method, and the cytotoxic activity was performed using MTT and XTT assays. The primary bioassay results indicated that 2-amino-4-oxy-diarylquinolines possess moderate inhibitory properties against HIV-1 RT. Molecular docking results showed that 2-amino-4-oxy-diarylquinolines 8(a-d) interacted with the Lys101 and His235 residue though hydrogen bonding and interacted with Tyr318 residue though π-π stacking in HIV-1 RT. Furthermore, 8a and 8d were the most potent anti-HIV agents among the designed and synthesized compounds, and their inhibition rates were 34.0% and 39.7% at 1 μM concentration. Interestingly, 8a was highly cytotoxicity against MOLT-3 (acute lymphoblastic leukemia), with an IC 50 of 4.63±0.62 μg/mL, which was similar with that in EFV and TMC278 (IC 50 7.76±0.37 and 1.57±0.20 μg/ml, respectively). Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future. © 2019 Georg Thieme Verlag. All rights reserved. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Drug Research. Vol 69, No.12 (2019), p.671-682 | |
| dc.identifier.doi | 10.1055/a-0968-1150 | |
| dc.identifier.issn | 21949379 | |
| dc.identifier.other | 2-s2.0-85075814506 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14740/5695 | |
| dc.rights.holder | Scopus | |
| dc.subject.other | 4 (2',6' dimethyl 4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline | |
| dc.subject.other | 4 (2',6' dimethyl 4' cyanophenoxy) 2 chloroquinoline | |
| dc.subject.other | 4 (2',6' dimethyl 4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline | |
| dc.subject.other | 4 (2',6' dimethyl 4' cyanophenoxy) 6 nitroquinoline | |
| dc.subject.other | 4 (2',6' dimethyl 4' formylphenoxy) 2 (4'' cyanophenyl)aminoquinoline | |
| dc.subject.other | 4 (2',6' dimethyl 4' formylphenoxy) 2 chloroquinoline | |
| dc.subject.other | 4 (2',6' dimethyl 4' formylphenoxy) 6 (4" cyanophenyl)aminoquinoline | |
| dc.subject.other | 4 (2',6' dimethyl 4' formylphenoxy) 6 nitroquinoline | |
| dc.subject.other | 4 (4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline | |
| dc.subject.other | 4 (4' cyanophenoxy) 2 chloroquinoline | |
| dc.subject.other | 4 (4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline | |
| dc.subject.other | 4 (4' cyanophenoxy) 6 nitroquinoline | |
| dc.subject.other | 4 (4' formylphenoxy) 2 (4" cyanophenyl)aminoquinoline | |
| dc.subject.other | 4 (4' formylphenoxy) 2 chloroquinoline | |
| dc.subject.other | 4 (4' formylphenoxy) 6 (4'' cyanophenyl)aminoquinoline | |
| dc.subject.other | 4 (4' formylphenoxy) 6 nitroquinoline | |
| dc.subject.other | Anti human immunodeficiency virus agent | |
| dc.subject.other | Antileukemic agent | |
| dc.subject.other | Doxorubicin | |
| dc.subject.other | Efavirenz | |
| dc.subject.other | Etoposide | |
| dc.subject.other | Etravirine | |
| dc.subject.other | Nevirapine | |
| dc.subject.other | Nonnucleoside reverse transcriptase inhibitor | |
| dc.subject.other | Quinoline derivative | |
| dc.subject.other | Rilpivirine | |
| dc.subject.other | Unclassified drug | |
| dc.subject.other | Anti human immunodeficiency virus agent | |
| dc.subject.other | Benzoxazine derivative | |
| dc.subject.other | Efavirenz | |
| dc.subject.other | Etravirine | |
| dc.subject.other | Nevirapine | |
| dc.subject.other | Pyridazine derivative | |
| dc.subject.other | Quinoline derivative | |
| dc.subject.other | Reverse transcriptase, Human immunodeficiency virus 1 | |
| dc.subject.other | Rilpivirine | |
| dc.subject.other | RNA directed DNA polymerase | |
| dc.subject.other | RNA directed DNA polymerase inhibitor | |
| dc.subject.other | Antileukemic activity | |
| dc.subject.other | Antiviral activity | |
| dc.subject.other | Article | |
| dc.subject.other | Cell viability | |
| dc.subject.other | Comparative study | |
| dc.subject.other | Concentration response | |
| dc.subject.other | Controlled study | |
| dc.subject.other | Cytotoxicity | |
| dc.subject.other | Drug conformation | |
| dc.subject.other | Drug cytotoxicity | |
| dc.subject.other | Drug design | |
| dc.subject.other | Drug potency | |
| dc.subject.other | Drug protein binding | |
| dc.subject.other | Drug structure | |
| dc.subject.other | Drug synthesis | |
| dc.subject.other | Enzyme inhibition | |
| dc.subject.other | Enzyme linked immunosorbent assay | |
| dc.subject.other | Human | |
| dc.subject.other | Human cell | |
| dc.subject.other | Human immunodeficiency virus 1 | |
| dc.subject.other | Hydrogen bond | |
| dc.subject.other | IC50 | |
| dc.subject.other | Molecular docking | |
| dc.subject.other | Molecular hybridization | |
| dc.subject.other | MOLT-3 cell line | |
| dc.subject.other | MRC-5 cell line | |
| dc.subject.other | MTT assay | |
| dc.subject.other | Pharmacophore | |
| dc.subject.other | Structure activity relation | |
| dc.subject.other | XTT assay | |
| dc.subject.other | Chemistry | |
| dc.subject.other | Drug effect | |
| dc.subject.other | Human immunodeficiency virus 1 | |
| dc.subject.other | Human immunodeficiency virus infection | |
| dc.subject.other | Metabolism | |
| dc.subject.other | Molecular docking | |
| dc.subject.other | Tumor cell line | |
| dc.subject.other | Anti-HIV Agents | |
| dc.subject.other | Benzoxazines | |
| dc.subject.other | Cell Line, Tumor | |
| dc.subject.other | Diarylquinolines | |
| dc.subject.other | HIV Infections | |
| dc.subject.other | HIV Reverse Transcriptase | |
| dc.subject.other | HIV-1 | |
| dc.subject.other | Humans | |
| dc.subject.other | Molecular Docking Simulation | |
| dc.subject.other | Nevirapine | |
| dc.subject.other | Pyridazines | |
| dc.subject.other | Reverse Transcriptase Inhibitors | |
| dc.subject.other | Rilpivirine | |
| dc.title | Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| swu.datasource.scopus | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075814506&doi=10.1055%2fa-0968-1150&partnerID=40&md5=ff3b3822d05ec10d157aa7796904d722 |
